Alnylam Pharmaceuticals (ALNY) Stock Price, Quote & News

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products i...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 551 8200

Fax: 617 551 8101

Website: www.alnylam.com

Address:

675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States

zerodayrounder Jun. 4 at 5:09 PM

$ALNY (an OG Longwood / Dr Christoph Westphal) start up now 40B market cap and $REGN each announced big cancer drug licensing deals this morning. When $GSK / $SPRO / Immunitas -- or some other boston area oncology player? 🤔

0 · Reply

johnnygogogo Jun. 4 at 2:59 PM

$ALNY gets its $300 champagne back by saying the secret passcode to the algorithm narrative. (Don’t tell anybody but the secret passcode is “AI”) @skeezbag

0 · Reply

notreload_ai Jun. 4 at 2:37 PM

$ALNY partners with AI startup Inceptive in a deal worth up to $2 billion to accelerate discovery of next-generation RNAi therapeutics using powerful AI models. https://notreload.xyz/xy/alnylam-inceptive-2b-ai-deal-to-speed-up-rnai-drugs/

0 · Reply

judgeyoung2 Jun. 4 at 2:23 PM

Okay let’s put our brains together for tomorrow. SPX additions. $MRVL i think is almost guaranteed based on the movement in the past 2 months. stocks always front run their inclusion. on top of that, the MC is huge and they meet all requirements. AI hype also. the committee loves adding things at the top. $ALNY this is only high up as a candidate because it’s got good odds on Kalshi and analysts seem to think it’ll be in. $RDDT another hype stock that the committee might want. pretty sure they meet all requirements? odds are good on Kalshi also. $LNG this one has been waiting to be added for forever. it makes more sense than ever now that CTRA (another energy stock) is out of the index due to merging. $AFRM this one is volatile but i see it as a possibility. i definitely prefer it to SOFI for inclusion odds. P Everpure and FLEX. one of these will get in but we don’t care because they won’t pump since already in the mid cap 400.

5 · Reply

supplySHOCK Jun. 4 at 11:05 AM

$FSLR $RMBS $ARM $ALNY fact

0 · Reply

supplySHOCK Jun. 4 at 8:16 AM

$ARM $ALNY $AMAT $ALAB scape

0 · Reply

supplySHOCK Jun. 3 at 11:28 PM

$FSLR $RMBS $ARM $ALNY line

0 · Reply

zztopps Jun. 2 at 8:41 PM

$ALNY Biotechs slaughtered as AI continues to suck the air out of most growth sectors. Stubbornly higher interest rates not helpful either. Staying the course here as prospects and fundamentals remain strong. Adding here near 52 week lows.

0 · Reply

topstockalerts May. 28 at 8:45 PM

J.P. Morgan reinstated coverage on 14 large-cap biotech companies, saying the sector is nearing a major inflection point as strong drug pipelines increasingly translate into profitable and diversified businesses. The bank noted many biotech firms are approaching sustained profitability, supported by expanding product portfolios, improving margins, and upcoming clinical catalysts. The firm assigned Overweight ratings to Vertex Pharmaceuticals, Alnylam Pharmaceuticals, BeOne Medicines, United Therapeutics, Insmed, Ascendis Pharma, Jazz Pharmaceuticals, Ionis Pharmaceuticals, BioMarin Pharmaceutical, and Mirum Pharmaceuticals. Neutral ratings were maintained on BioNTech, Incyte, and Halozyme Therapeutics, while Moderna received an Underweight rating. J.P. Morgan highlighted Vertex’s expansion beyond cystic fibrosis, Alnylam’s strong Amvuttra growth, and continued momentum for BeOne Medicines and United Therapeutics. $VRTX $ALNY $ONC $UTHR $INSM

0 · Reply

OffHisGame88 May. 28 at 7:05 PM

$ALNY When they're sleeping on you.... tuck em in

0 · Reply

Alnylam, Inceptive sign up to $2 billion AI drug discovery deal

2026-06-03T20:50:11.000Z - 1 day ago

Alnylam, Inceptive form strategic AI collaboration

Jun 3, 2026, 4:45 PM EDT - 1 day ago

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

May 20, 2026, 10:30 AM EDT - 16 days ago

Alnylam Pharmaceuticals Transcript: AGM 2026

May 19, 2026, 8:30 AM EDT - 17 days ago

Alnylam Issues 2025 Corporate Responsibility Report

2026-05-18T20:25:59.000Z - 17 days ago

Alnylam initiated with a Buy at Citi

May 13, 2026, 1:40 PM EDT - 22 days ago

Alnylam Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T09:53:47.000Z - 24 days ago

Alnylam announces new analyses from HELIOS-B study of vutrisiran

May 12, 2026, 2:30 AM EDT - 24 days ago

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

2026-05-07T18:59:32.000Z - 4 weeks ago

MBX Biosciences appoints Mark Soued as chief commercial officer.

MBX

May 7, 2026, 8:00 AM EDT - 4 weeks ago

Alnylam to Webcast Presentations at Upcoming Investor Conferences

May 4, 2026, 8:30 AM EDT - 4 weeks ago

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

2026-05-01T15:51:39.000Z - 4 weeks ago

Alnylam price target raised to $370 from $360 at Morgan Stanley

2026-05-01T14:21:06.000Z - 5 weeks ago

Alnylam price target lowered to $447 from $448 at Bernstein

2026-04-30T16:59:31.000Z - 5 weeks ago

Alnylam reports Q1 EPS $1.99, consensus $1.47

Apr 30, 2026, 8:30 AM EDT - 5 weeks ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 5 weeks ago

Alnylam Pharmaceuticals Quarterly report: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 5 weeks ago

Alnylam Pharmaceuticals Slides: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 5 weeks ago

Alnylam Pharmaceuticals Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

Apr 16, 2026, 8:00 AM EDT - 7 weeks ago

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

2026-04-13T13:43:03.000Z - 7 weeks ago

Alnylam price target lowered to $505 from $515 at Truist

Apr 6, 2026, 2:14 PM EDT - 2 months ago

An S&P 500 change may be imminent. These stocks are leading contenders to join the index.

IVV SPXL SPY SSO UPRO VOO FERG

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Alnylam Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Alnylam Pharmaceuticals Proxy statement: Proxy filing

2026-04-06T11:05:55.000Z - 2 months ago

BioCryst appoints Sandeep Menon as chief research and development officer

BCRX

2026-03-30T17:11:15.000Z - 2 months ago

Alnylam presents new data on vutrisiran in ATTR-CM at ACC.26

2026-03-30T17:10:33.000Z - 2 months ago

Alnylam presents new data on potential of zilebesiran for hypertension

Mar 30, 2026, 1:00 PM EDT - 2 months ago

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

Mar 24, 2026, 9:30 AM EDT - 2 months ago

Alnylam Pharmaceuticals Transcript: Status update

Mar 24, 2026, 9:30 AM EDT - 2 months ago

Alnylam Pharmaceuticals Press release: Status update

Mar 24, 2026, 9:30 AM EDT - 2 months ago

Alnylam Pharmaceuticals Slides: Status update

Mar 24, 2026, 9:00 AM EDT - 2 months ago

Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis

2026-03-24T11:40:13.000Z - 2 months ago

Alnylam announces set of efforts to improve care for patients with ATTR-CM

Mar 24, 2026, 7:30 AM EDT - 2 months ago

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

2026-03-16T09:25:22.000Z - 2 months ago

Alnylam downgraded to Hold from Buy at Jefferies

Mar 11, 2026, 11:55 AM EDT - 3 months ago

How Alnylam Stock Weathers Market Shocks

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Alnylam to Webcast TTR Investor Webinar

Mar 5, 2026, 9:10 AM EST - 3 months ago

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

TNYA

2026-03-05T13:52:56.000Z - 3 months ago

Tenaya Therapeutics enters research collaboration with Alnylam

TNYA

Mar 5, 2026, 8:30 AM EST - 3 months ago

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

TNYA

Mar 2, 2026, 9:10 AM EST - 3 months ago

Alnylam Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 10:00 AM EST - 3 months ago

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

2026-02-17T12:20:41.000Z - 3 months ago